Downregulated expression of metallothionein and its clinicopathological significance in hepatocellular carcinoma

Aim:  Metallothionein (MT) protein is related to different stages of development and progression of various tumors in humans. The aim of the present study was to investigate expression and localization of MT and their association with clinicopathological characteristics in hepatocellular carcinoma (HCC).

[1]  J. Koropatnick,et al.  Radiation exposure does not alter metallothionein III isoform expression in mouse brain , 2000, Biological Trace Element Research.

[2]  Sean Jiang,et al.  Interaction of metallothionein with tumor suppressor p53 protein , 2006, FEBS letters.

[3]  J. Woodgett,et al.  Expression of Wnt-signaling pathway proteins in intraductal papillary mucinous neoplasms of the pancreas: a tissue microarray analysis. , 2006, Human pathology.

[4]  W. Cong,et al.  Expression of aspartyl beta-hydroxylase and its clinicopathological significance in hepatocellular carcinoma , 2006, Modern Pathology.

[5]  T. Nielsen,et al.  MDM2 protein expression is a negative prognostic marker in breast carcinoma , 2006, Modern Pathology.

[6]  K. Petraki,et al.  Hepatic expression of the proliferative marker Ki‐67 and p53 protein in HBV or HCV cirrhosis in relation to dysplastic liver cell changes and hepatocellular carcinoma , 2005, Journal of viral hepatitis.

[7]  N. Miura,et al.  Gene expression profiles in the liver and kidney of metallothionein-null mice. , 2005, Biochemical and biophysical research communications.

[8]  H. Fukuda,et al.  Immunohistochemical metallothionein expression in hepatocellular carcinoma: relation to tumor progression and chemoresistance to platinum agents , 2004, Journal of Gastroenterology.

[9]  S. Theocharis,et al.  Metallothionein expression in human neoplasia , 2004, Histopathology.

[10]  Pei-yu Huang,et al.  [Correlation analysis among expression of ERCC-1, metallothionein, p53 and platinum resistance and prognosis in advanced non-small cell lung cancer]. , 2004, Ai zheng = Aizheng = Chinese journal of cancer.

[11]  A. Jayasurya,et al.  Metallothioneins in human tumors and potential roles in carcinogenesis. , 2003, Mutation research.

[12]  Y. Kondo,et al.  Optimal administration schedule of cisplatin for bladder tumor with minimal induction of metallothionein. , 2003, The Journal of urology.

[13]  S. Garrett,et al.  Metallothionein isoform 1 and 2 gene expression in a human urothelial cell line (UROtsa) exposed to CdCl2 and NaAsO2. , 2003, Journal of toxicology and environmental health. Part A.

[14]  P. Tan,et al.  Differential expression of metallothionein 1 and 2 isoforms in breast cancer lines with different invasive potential: identification of a novel nonsilent metallothionein-1H mutant variant. , 2003, The American journal of pathology.

[15]  W. Hou,et al.  Molecular cloning of two metallothionein-like protein genes with differential expression patterns from sweet potato (Ipomoea batatas) leaves. , 2003, Journal of plant physiology.

[16]  D. Rimm,et al.  Automated subcellular localization and quantification of protein expression in tissue microarrays , 2002, Nature Medicine.

[17]  S. Ottonello,et al.  Differential Expression of a Metallothionein Gene during the Presymbiotic versus the Symbiotic Phase of an Arbuscular Mycorrhizal Fungus1 , 2002, Plant Physiology.

[18]  Geng-Wen Huang,et al.  Metallothionein expression in hepatocellular carcinoma. , 2002, World journal of gastroenterology.

[19]  Y. Doki,et al.  Prediction of the response to chemoradiation and prognosis in oesophageal squamous cancer , 2002, The British journal of surgery.

[20]  K. Ghoshal,et al.  Analysis of promoter methylation and its role in silencing metallothionein I gene expression in tumor cells. , 2002, Methods in enzymology.

[21]  S Thameem Dheen,et al.  Metallothionein 2A expression is associated with cell proliferation in breast cancer. , 2002, Carcinogenesis.

[22]  P. Hainaut,et al.  Zinc binding and redox control of p53 structure and function. , 2001, Antioxidants & redox signaling.

[23]  D. Lamm,et al.  Metallothionein isoform 1 and 2 gene expression in the human bladder: evidence for upregulation of MT-1X mRNA in bladder cancer. , 2001, Cancer detection and prevention.

[24]  A. Jayasurya,et al.  Proliferative potential in nasopharyngeal carcinoma: correlations with metallothionein expression and tissue zinc levels. , 2000, Carcinogenesis.

[25]  E. J. Cornish,et al.  Metallothionein isoform expression by breast cancer cells. , 2000, The international journal of biochemistry & cell biology.

[26]  H. Baba,et al.  Reversal of metallothionein expression is different throughout the human myocardium after prolonged left-ventricular mechanical support. , 2000, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[27]  K. Suzuki,et al.  Nuclear trafficking of metallothionein: possible mechanisms and current knowledge. , 2000, Cellular and molecular biology.

[28]  K. Ghoshal,et al.  Suppression of Metallothionein Gene Expression in a Rat Hepatoma Because of Promoter-specific DNA Methylation* , 2000, The Journal of Biological Chemistry.

[29]  Stanley R. Hamilton,et al.  Pathology and genetics of tumours of the digestive system , 2000 .

[30]  R. Reddel,et al.  Downregulation of metallothionein-IIA expression occurs at immortalization , 1999, Oncogene.

[31]  M. Cherian,et al.  Metallothionein and apoptosis in primary human hepatocellular carcinoma (HCC) from northern China. , 1998, Anticancer research.

[32]  N. Horiike,et al.  Immunohistochemical localization of metallothionein in hepatocellular carcinoma: preferential expression in non-cancerous cirrhotic nodules. , 1998, Oncology reports.

[33]  J. Kononen,et al.  Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.

[34]  R H Hruban,et al.  Gene expression profiles in normal and cancer cells. , 1997, Science.

[35]  D. Sens,et al.  Isoform-specific expression of metallothionein mRNA in the developing and adult human kidney. , 1996, Toxicology letters.

[36]  Simon C Watkins,et al.  Metallothionein localization and cisplatin resistance in human hormone-independent prostatic tumor cell lines. , 1995, Cancer research.

[37]  M. Fiorentino,et al.  Overexpression of p53 protein and Ki67 proliferative index in hepatocellular carcinoma: , 1994, Pathology international.

[38]  M. Waalkes,et al.  Methylation status and organization of the metallothionein-I gene in livers and testes of strains of mice resistant and susceptible to cadmium. , 1988, Toxicology.